We have identified a gene, ST18 (suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type (configuration Cys-X 5 -Cys-X 12 -His-X 4 -Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.
Introduction
Recent cytogenetic and molecular studies have suggested that many genetic and epigenetic events might be involved in breast cancer tumorigenesis. In particular, aberrations and allelic imbalances/loss of heterozygosity (LOH) of human chromosome 8 are common in a variety of human malignancies including breast cancer (Osborne and Hamshere, 2000) . Most of the numerous LOH studies on chromosome 8 were directed to the short arm of chromosome 8 and led to the identification of a number of discrete LOH regions as potential sites for tumor suppressor genes in sporadic and inherited breast cancer (Seitz et al., 1997; Adelaide et al., 1998; Wang et al., 1999) . Although patterns of 8q allelic imbalances have not been investigated extensively in breast cancer, there is experimental evidence that two regions at 8q11-q12 and 8q23-q24 are commonly deleted in this solid tumor (Dahiya et al., 1998) . In the present study, we have identified a homozygous deletion, mapping within the 8q11 region, around the marker D8S1110, in a breast cancer tumor. This site harbors the gene ST18 (suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein) (also named KIAA0535 or ZNF387), which shows similarity to members of the NZF/MyT1 family of zinc-fingercontaining transcription factors (Yee and Yu, 1998) . Our in vitro and in vivo data suggest that ST18 may contribute to the development of breast cancer.
Results

LOH analyses in breast tumors define a region of 8q11.2 containing ST18
We previously reported LOH occurring at high frequency within the 8p12-p21 region in a panel of familial and sporadic breast cancers (Seitz et al., 1997) . In the course of these studies, we found a commonly imbalanced region around the marker D8S1110, now mapped to 8q11.2, reaching 47 and 54% LOH in familial and sporadic breast tumors, respectively. One of the familial tumors, case 36/300, failed repeatedly to amplify a PCR product at the D8S1110 locus, indicating a homozygous deletion at D8S1110 in this tumor. The borders of the region are defined by the markers D8S538 and D6S601. This finding prompted us to search for candidate genes. A PAC/BAC contig was established around the marker D8S1110 with PAC 287G17 as center clone. Fluorescence in-situ hybridization (FISH) analysis showed that PAC 287G17 maps to the long arm of chromosome 8 in close proximity to the centromere. The PAC clone was then sequenced using a shotgun approach. In addition, exon trapping was performed. Homology searches using public databases identified an uncharacterized cDNA of 6183 bp, named KIAA0535 (Nagase et al., 1998) and later ZNF387. Using exon walking, the entire genomic organization of the gene was identified. The gene consists of 26 exons and spans approximately 300 kb (Figure 1) . It codes for a putative protein of 1047 aa in size. The protein has six zinc-fingers of the C2HC class (configuration Cys-X 5 -Cys-X 12 -His-X 4 -Cys) arranged in two widely separated clusters and an SMC (structural maintenance of chromosomes) domain. The gene was named ST18 for suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein (GenBank Accession no. NM_014682).
Mutational analysis of the ST18 gene in breast tumor and breast cancer cell lines SSCP analysis was performed for the entire coding region of the ST18 gene in 70 primary breast tumors, seven different breast cancer cell lines and in the nontransformed breast cell line MCF-10A. Detailed description of the primary tumors and their clinical parameters are already described elsewhere (Seitz et al., 2000) . Although we detected a number of aberrantly migrating bands sequencing of those bands, yielded only three different nucleotide sequence alterations, two of which occurred in noncoding regions. The first sequence variation in intron 7 (c.739-86 C>G) was found in only one tumor and the corresponding matched normal tissue. The second sequence variant in intron 17 (c.2852 þ 7G>A) was detected in about 30% of the tumors as well as the normal cells surrounding the tumors. The third sequence variation occurred in exon 10 (c.1017C>T) of the breast cancer cell line BT-20 but did not result in an amino-acid exchange (p.N111N).
ST18 mRNA is downregulated in the majority of breast tumor tissues and breast cancer cell lines Northern blot analysis (MTN, Clontech) showed an ST18 transcript of about 6.3 kb in the heart, liver, kidney, skeletal muscle, pancreas, testis, ovary, and prostate tissue that was expressed at very low levels in comparison to b-actin (data not shown). In mammary epithelial and breast cancer cells (Invitrogen), only very small amounts of a 6.3 kb ST18 transcript or no bands were visible. We could not detect alternatively spliced forms of the ST18 transcript on Northern blots.
In chip array experiments (U133A, Affymetrix) with cRNA from mammary cells, the signals for this gene are too weak and called absent. Since the ST18 message is rare, mRNA expression analysis of ST18 was performed using quantitative RT-PCR in a panel of 12 normal breast epithelial tissue samples and matched tumor samples from the same patients. ST18 mRNA was present in both normal and malignant breast tissue samples. However, the ST18 transcript was downregulated in the majority of breast cancer samples (Figure 2 ). In addition, ST18 mRNA was downregulated (range 4-205-fold) in the breast cancer cell lines T47D, CAL51, MDA-MB231, and MCF-7 in comparison to the nontumorigenic breast epithelial cell line MCF-10A. MCF-7 displayed the lowest endogenous ST18 expression in comparison to MCF-10A and was therefore selected for transfection experiments.
ST18 promoter region is highly methylated in primary breast tumors and breast cancer cell lines
We then asked the question whether epigenetic methylation may be responsible for the downregulation of the ST18 mRNA in tumors. We examined the methylation status of 18 CpG dinucleotides of the closest island 5 0 to exon1 in six primary breast tumors and their matched normal tissues. In the tumors, about 78% (65-86%) of the CpGs in the sequenced clones were found to be methylated, while in the corresponding normal tissues only about 19% (11-29%) of the sites in the clones were methylated (Figure 2 ). We then examined another 20 breast tumor samples and found a similar high methylation rate of about 82% (69-96%) for the CpG (Figure 3 ). The increase of ST18 expression was especially high in MDA-MB231 and MCF-7 cells.
Subcellular localization defines ST18 as a nuclear protein
We have constructed GFP-expression vectors containing the full-length coding ST18 cDNA. The ST18 fusion vectors as well as the original GFP vectors were transfected into MCF-7 cells. Overexpressed ST18-GFP fusion protein was identified almost exclusively in the nucleus of the transfected cells. In contrast, MCF-7 cells transfected with the GFP-control plasmid displayed a disperse distribution of GFP fluorescence within the cells (data not shown). No difference in subcellular localization was observed with fusion constructs in which ST18 was joined to the vector in the Cterminal or in the N-terminal position.
In order to detect the endogenous ST18 protein by immunocytochemistry, we produced monoclonal antibodies that recognize amino acids 673-687 (peptide 978) of the ST18 protein. The antibodies were tested for their specificity using an ELISA. In Western blots a clear band of about 105 kDa could be observed. In both normal breast cells (MCF-10A) as well as in various breast cancer cells (CAL51, MDA-MB231), mAB B101-DD3 detected ST18 protein predominantly in the nucleus of the cells (Figure 4a , e, g), although staining of the ST18 protein in the breast cancer cell lines was much weaker (Figure 4e , g). Immunocytochemistry with a different antibody (mAB B101-DD8) confirmed that ST18 is a nuclear protein (Figure 4c ).
Expression of ectopical ST18 suppresses transformed and tumorigenic properties of MCF-7 cells
To determine whether increased ST18 expression may change the phenotype of MCF-7 breast cancer cells expressing low levels of ST18 mRNA, we transfected MCF-7 cells in two independent experiments with expression constructs carrying the cloned ST18 cDNA. In comparison to the sequenced wild type clones one of the constructs contained a silent mutation (c.1740C>T; p.I352I) that occurred during cloning. Expression of ectopic ST18 in the transfected cells was confirmed using sequencing of cDNA (around the silent mutation) as well as QRT-PCR showing hundred-fold higher ST18 expression in comparison to the parental cell line as well as the clones transfected with an empty vector. In monolayer cultures, MCF-7/ST18 transfectants exhibited a slightly reduced growth rate in comparison to empty vector MCF-7 transfectants (data not shown). However, significant differences were found when we performed colony formation assays on soft agar. In this assay, on average 400 colonies were observed with MCF-7 cells transfected with ST18 compared with 3800 colonies formed by MCF-7/empty vector transfectants. In addition to the 90% decrease in colony formation, MCF-7/ST18 transfectants also formed much smaller colonies than did the original cells or cells transfected with vector only.
The strong decrease of growth in soft agar prompted us to examine the consequences of forced ST18 expression in MCF-7/ST18 cells on tumorigenic properties in vivo. MCF-7 and MCF-7/ST18 containing cells were injected subcutaneously into 6-8-week-old nude mice. Tumor growth was monitored over a period of 8 weeks and tumor size was measured once a week as described in 'Materials and methods'. At 14 days after injections, tumors generated by the MCF-7 cells were palpable and grew progressively in size afterwards. In contrast, the MCF-7/ST18 clones expressing ectopical ST18 did not produce progressively growing tumors or did so to a very slight extent (Table 1) .
Discussion
In this study, we have identified a homozygous deletion in a breast cancer specimen around the marker D8S1110 on chromosome 8q11.2, a well-known cytogenetic region on chromosome 8, where we and others observed frequent allelic imbalances in breast cancer as well as in other types of solid tumors (Dahiya et al., 1998; Osborne and Hamshere, 2000) . In search of a candidate gene within this region, we detected ST18. To date, several other genes within the 8q11-q12 region were identified, which may also be involved in the tumorigenesis of different types of cancer, including acute lymphoblastic leukemia (Bardet et al., 2002) and lipoblastoma (Astrom et al., 2000) . Recently, the gene RB1CC1, located on 8q11.2, was found to be frequently mutated in human breast cancer (Chano et al., 2002) . ST18 is located in the vicinity of RB1CC1, approximately 350 kb distal. Both genes are arranged in a head to tail configuration and do not share a common promoter region.
The full-length ST18 cDNA encodes a protein with six zinc-fingers of the C2HC type (configuration Cys-X 5 -Cys-X 12 -His-X 4 -Cys). ST18 shows 86.1% identity to the neural zinc-finger protein (NZF3) of the rat (Yee and Yu, 1998) and 84.9% identity with its mouse ortholog, St18 (AJ536155). The identity is especially high in the zinc-finger regions as well as the SMC domain. The high grade of conservation in evolution is underlined by the presence of this special zinc-finger configuration in Caenorhabditis elegans (NP_492622), Drosophila melanogaster (AAF45913) and Anopheles gambiae (EAA12108). In the human genome, two other genes with this zinc-finger motif exist, however, showing a different clustering. MYT1 (NM_00435) is located on chromosome 20 and MYT1-L (AF036943) (also named KIAA1106) on chromosome 2. These genes are involved in neural (Kim et al., 1997) and endocrine pancreatic development (Gu et al., 2004) .
Extensive mutation analysis was performed in 70 primary breast tumor samples and seven breast cancer cell lines. Altogether, we found three sequence polymorphisms. In an SNP database (http://www.ncbi.nlm.-nih.gov/SNP/), only two sequence alterations in the coding region of ST18 are listed having average allele frequencies of (0.99;0.01) and (0.91;0.09), respectively. These sequence alterations could not be detected in our samples. The very small number of polymorphisms in the coding region underlines the high grade of conservation of ST18 in evolution. In summary, no loss of function mutations or other alterations were identified that were restricted to the tumor samples.
ST18 transcripts are expressed at low levels in a number of different tissues, including mammary epithelial cells. QRT-PCR analysis showed that ST18 mRNA was significantly downregulated both in the majority of sporadic breast tumors as well as in various breast cancer cell lines, which may be caused by epigenetic changes in the promoter region of the ST18 gene. Recent reports have demonstrated that hypermethylation of CpG islands represents an important mechanism to inactivate expression of specific genes during tumorigenesis. In particular, lack of expression of a number of proteins in breast cancer and other solid tumors has been directly linked to promoter hypermethylation (Yang et al., 2001; Widschwendter and Jones, 2002; Esteller, 2003) . Studies have shown that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived (Ueki et al., 2002) , suggesting that ST18 may be inactivated in the early stages of breast tumorigenesis. To examine ST18 for potential growth-and tumorsuppressive effects, we transfected ST18 cDNA into MCF-7 breast cancer cells, expressing low levels of ST18. We demonstrated that ST18 expression induces a strong decrease of colony formation of MCF-7 cells in soft agar in vitro. More importantly, tumorigenicity of the MCF-7 breast cancer cell line was dramatically reduced by ectopically expressed ST18 in a mouse model. Such a remarkable difference in tumor growth rate and size again indicates that ST18 behaves as a suppressor of tumor growth.
At present, we do not know how ST18 might function as a tumor suppressor. Zinc coordinated fingers are the most common DNA-binding motifs among eucaryotic transcription factors and can be classified based on the number and position of the cysteine and histidine residues of the zinc-fingers. In accordance with their structural diversity, zinc-finger proteins play important roles in cell growth, differentiation, and development. The zinc-finger clusters are the most conserved regions among the NZF/MyT family and these clusters have been shown to bind to very similar target sequences. However, differences in their binding affinity and competition with other factors for closely related recognition sequences may allow them to regulate genes differently.
Another interesting domain of the ST18 protein is located at the C-terminal part and shows homology to a motif of structural maintenance of chromosomes (SMC) proteins. SMC proteins appear to regulate chromosome morphology, and they have been implicated in chromosome condensation, recombination, repair, gene dosage compensation, as well as sister chromatid cohesion (Haering and Nasmyth, 2003) . Meanwhile, mistakes during mitotic chromosome segregation are frequently associated with malignant tumor cells and are thought to facilitate their evolution (Jallepalli and Lengauer, 2001 ). These specific features remain to be demonstrated for ST18 and may lead to the elucidation of novel pathways in breast cancer development.
Materials and methods
Primary and familial breast cancer samples
Primary breast cancers were retrieved from pathology archives at the Robert Ro¨ssle Hospital Berlin, Germany. Familial breast cancers are from German families collected in the course of a nationwide project at the Department of Tumor Genetics of the Max-Delbru¨ck-Center for Molecular Medicine, Berlin, Germany. Detailed description of the samples is published (Seitz et al., 2000) . All samples were coded, and the confidentiality of the clinical information was preserved. The study was performed with the approval of the local ethics committee (AA2/96/23).
Preparation of DNA and RNA
Frozen tissue samples were sectioned with a cryostate microtome. Specimens were taken adjacent to a hematoxylin-eosin-stained section assessed for tumor cell content, which was estimated to be more than 50%. DNA was extracted by standard techniques as described (Seitz et al., 1997) . Total RNA was extracted from tissue specimens by using the TRIZOL reagent (Gibco-BRL, Karlsruhe, Germany), following the manufacturer's instruction.
Cell culture
The breast cancer cell lines MCF-7, T47D, BT-20, MDA-MB-231, MDA-MB-468, and the mammary epithelial cell line MCF-10A were obtained from the American Type Culture Collection (ATCC) (Rockville, MD, USA). The cancer cell line CAL51 was kindly provided by Dr Gioanni (Centre AntaineLacassagne, Nice, France), and the cell line R103 by Dr Fichtner (Max-Delbrueck Center, Berlin, Germany). MDA-MB231, BT-20, and T47D were cultured in RPMI 1640 plus 10% fetal calf serum (FCS), whereas CAL51, R103, and MCF-7 were cultured in Dulbecco's modified Eagle's medium (D-MEM) plus 10% FCS.
LOH analysis
The primer pair for the polymorphic marker D8S1110 and primers D8S531, D8S1745, D8S538, D8S1098, D8S601, and D8S1718 used in this study were synthesized according to the published primer sequences (GDB); one primer was fluorescence labeled. Conditions for PCR were as described (Seitz et al., 1997) . The PCR products were fractionated on denaturing polyacrylamide gels using an ABI 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). LOH data were analysed automatically by comparing nontumorous and tumor tissue allele peak sizes, heights, and area ratios. Intensity or signal ratio differences of 35% or more were considered sufficient for LOH assignment.
DNA samples showing complete absence of amplification for the tested marker were reexamined using multiplex PCR. D10S1426, a microsatellite marker mapped to 10p11, was used as the control locus in the multiplex reactions. The failure to produce a PCR product from one of the two amplicons in the multiplex reaction was interpreted as homozygous loss of the sequence that failed to amplify.
PAC identification
A human PAC library (Genome Systems, St Louis, MO, USA) was screened by a down to the well approach using the primers for the polymorphic marker D8S1110. Selected clones were confirmed by sequencing.
Fluorescence in-situ hybridization (FISH)
Cytogenetic assignment of PAC clone 287G17 by indirect FISH to normal metaphases was performed as described recently using biotinylated PAC DNA as probe (Zhang et al., 1999) . A digoxigenin-labeled centromeric probe for chromosome 8 (Oncor, Gaithersburg, MD, USA) served as internal control.
Exon trapping
DNA from the PAC 287G17 was digested with enzymes BamHI, EcoRI, Pstl, and Xhol (New England Biolabs, Beverly, MA, USA), subcloned into pSPL3b vector (Burn et al., 1995) , and used to transform DH-5a bacteria. DNA from the clones were sequenced and transfected into COS-7 cells by lipofectamin (Janke et al., 2000) . After 48 h growth, the cells were harvested and total RNA prepared by the RNAzol method (Gibco-BRL). Reverse transcription was performed with primer SA4 for 30 min at 421C with ST18 at human chromosome 8q11.2 B Jandrig et al Superscript II reverse transcriptase (Gibco-BRL). Products of RT-PCR with primers SA4 and SD6 were cloned into TA vectors (Invitrogen, Groningen, Netherlands) and sequenced on an ABI 377.
Genomic sequencing
The PAC was nebulized (Hydroshear, GeneMachines, San Carlos, CA, USA) and subcloned into pUC18 vector. A total of 3000 colonies were selected and plasmid DNA was prepared using a QIAGEN 9600 robot (Qiagen, Hilden, Germany) and QIAGEN Turbo and Milipore kits, respectively. Dye terminator sequencing was carried out by using Big Dye chemistry (Applied Biosystems). The gels were run on ABI 377 sequencers and data were assembled and edited using the GAP4 program (Bonfield et al., 1995) .
ST18/St18 sequence alignment
To identify the complete mouse St18 cDNA (MGI: 2446700), we performed a BLAST homology search of public databases using the human ST18 cDNA (HGNC ID: 18695) sequence as a query sequence. We used gene prediction and human-mouse homology on the genomic level as well as available mouse EST information to assemble the complete sequence. DNA and deduced amino-acid sequences were analyzed using the DNASIS sequence analysis software and the PSORTII program.
Mutation analysis
Coding exons were amplified by PCR with primers located in the intron regions (primer sequences and PCR conditions are available on request). The amplification products were purified and run on SSCP gels at temperatures between 7 and 301C (SSCP buffer conditions as described) (Jandrig et al., 1996) . PCR products showing mobility shifts were subjected to direct sequencing using ABI 377 sequencers.
RT-PCR and TaqMan analysis
RNA was reverse transcribed as described (Janke et al., 2000) . RT-PCR results were expressed as semiquantitative values based on the ratio of the intensity of ST18 and GAPDH PCR products analysed on ethidium bromide-stained agarose gels using the Quantity One Gel Analyzer System (Biorad, Munich, Germany). Real-time PCR was performed using the TaqMan Universal PCR Master Mix kit on an ABI Prism 7700 Sequence Detection System (Applied Biosystems). Primers and probes for ST18 were chosen with the assistence of the computer program Primer Express (Applied Biosystems). The nucleotide sequences of primers and probe were as follows:
0 . To avozid amplification of contaminating genomic DNA, one of the two primers was placed in a different exon. The thermal cycling conditions comprised an initial denaturation step at 951C for 10 min and 40 cycles at 951C for 15 s and 601C for 1 min. Experiments were performed with triplicates for each data point and in duplicate. We also quantified transcripts of the genes GAPDH, encoding human glyceraldehyde-3-phosphate dehydrogenase, as well as b-actin as endogenous RNA controls using VIClabeled PDARs (Applied Biosystems). Each sample was normalized on the basis of its control gene content.
Northern blot analysis
Human Multiple Tissue Northern (MTN) blots (Clontech, Palo Alto, CA, USA), Northern Territory Human Breast Tumor Blots (Invitrogen), and a 32 P-labeled 675 bp PCRderived fragment (primers 5 0 -GAAATCATGATAAAACC-TATG-3 0 and 5 0 -CACAACCTCGCTCAG-3 0 ) as a probe for detection of ST18 were used together with the ExpressHyb hybridization solution (Clontech) following the manufacturer's instructions. As control, the human b-actin cDNA probe (Clontech) was used.
Sodium bisulfite treatment and methylation status analysis
Screening of the genomic sequence upstream of ST18 for CpG islands was performed with standard parameters (window size 100 bp, 50% minimum G/C content, observed/expected 0.6). There were two hits in the vicinity of the mRNA 5 0 end. For analysis, we choose the CpG island consisting of 20 CpGs. In total, 4 mg of DNA from blood, tumors, or cells were incubated in 50 ml of 3 M NaOH for 20 min at 421C for denaturation. In total, 60 ml of 1 M hydroquinone and 440 ml of 2.5 M sodium metabisulfite solution were added directly to the denaturated DNA, mixed, covered with 200 ml mineral oil, and incubated in the dark for 15-24 h at 50 1C. After incubation, DNA was desalted by the Wizard DNA purification kit (Promega, Madison, WI, USA) according to the manufacturer's instructions and eluted in 100 ml of 1 mM Tris-HCl (pH 8.0). Eluted DNA was desulfonated by adding 11 ml of 3 M NaOH at 371C for 20-25 min, neutralized by adding 47 ml of 10 M ammonium acetate, ethanol precipitated and dissolved in 40 ml of 1 mM Tris-HCl (pH 8.0), and used immediately or stored at À201C. PCR reactions were carried out in a 20 ml volume containing 7 ml of bisulfite-treated DNA, 5 pmol of each primer (primer sequences are available on request, PCR fragment covers 18 CpGs), 200 mM of each dNTP, and 1.5 U Taq polymerase. Initial denaturatuion was performed at 961C for 2 min, followed by 45 cycles of 15 s at 951C, 30 s at 561C, and 2 min at 721C with a final extension at 721C for 10 min. PCR fragments were cloned using the TA cloning kit (Invitrogen). DNA from about 10 colonies of each treated DNA was sequenced by use of BigDye chemistry on ABI377 sequencers.
Construction of ST18 plasmids
A cDNA fragment covering the whole coding region of ST18 was amplified by the Expand Long Template PCR System (Roche, Mannheim, Germany) according to the application protocol using the primers 5 0 -AGACGTCAAGTACAAG-TACTAGG-3 0 and 5 0 -GCAACCTCCACGCCTTAG-3 0 . PCR fragment was cloned into a pCR-XL-TOPO vector (Invitrogen) and sequenced to rule out mutations. A wild-type fragment was then subcloned into the vectors pcDNA3 (Invitrogen), pEGFP-N2, and pEGFP-C1 (Clontech), respectively, using HindIII and XhoI sites.
Transfection assay
To generate pcDNA3-ST18-and pEGFP-ST18-transfected MCF-7 cells, 10 mg of plasmid DNA was transferred in 3 Â 10 5 cells using lipofectin (Invitrogen) according to the manufacturer's instructions. After 48 h, the cells were seeded in 60 mm plates at a density of 1 Â 10 5 cells/plate. Selection for transfected cells was carried out in a medium containing 600 mg/ml G418 (Invitrogen). Experiments with pcDNA3-ST18 were done twice.
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In vitro growth assay
A suspension of 2.5 Â 10 4 cells in 0.3% agarose (Sigma, Deisenhofen, Germany) supplemented with DMEM culture medium was layered on a 0.6% agarose-medium base layer in a 60 mm dish. After incubation of 10-14 days at 371C in a 5% CO 2 incubator, colonies larger than 0.5 mm were counted.
Tumorigenicity test
Suspensions of 10 5 , 10 6 , and 10 7 cells, respectively, in a volume of 0.2 ml of serum-free medium were injected subcutaneously into the left inguinal region of 6-8-week-old female immunedeficient nude mice (Shoe:NMRI-nu/nu -DIMED Scho¨n-walde GmbH, Germany). To favor the growth conditions, all animals were administered 17b-estradiol pellets subcutaneously into the neck region (90-day release pellets; 0.72 mg/ pellet; Innovative Research of America, Sarasota, FL, USA). For every cell clone, three animals were treated. Tumor diameters were measured once weekly using a caliper-like mechanical instrument. The experiments were approved by the local licensing committee (G0439/98).
Immunization and hybridoma technology, immunoassay
A peptide with the sequence Mca-gly-SKTHGKTEEE-KEKDP-amid (designated peptide 978) was synthesized by BIOSYNTAN, Berlin, Germany. This peptide was conjugated via the chloroacetyl group to iminothiolane-modified carrier proteins (bovine serum albumin, BSA and keyhole limpit hemocyanin, KLH), using Traut's reagent (Sigma-Aldrich Taufkirchen, Germany) according to the method of Lindner and Robey (1987) . C57Bl6 mice were immunized twice with the KLH-peptide conjugate (first immunization with complete Freund's adjuvant) to obtain polyclonal antibodies. For hybridoma production, the mice were immunized a third time without adjuvant. Spleen cells of the immunized mice were fused with myeloma X63-Ag8.653 cells using polyethylene glycol 1550 (Sigma-Aldrich). Selected hybrids were cultivated, cloned, subcloned, and stored frozen in liquid nitrogen according to standard methods. Antibodies were purified from culture media by protein A affinity chromatography. Serum from immunized mice and monoclonal hybridoma antibodies were tested for antibodies in a solid-phase enzyme immunoassay as described (Bo¨ttger et al., 1999) . Mice immunized with the KLH-peptide 978 conjugate showed a strong antibody response against BSA-peptide 978 conjugate (positive reactivity of the serum when diluted more than 1-10 000). Two fusions were performed which resulted in more than 10 clones producing monoclonal antibodies reactive with BSA-peptide 978 adsorbed to the solid phase. The antibodies were then tested for reactivity with mammary cancer cells in immunohistology.
Western blotting
Cells were washed twice with PBS and lysed in a buffer containing 10 mM Tris/HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5mM EDTA, 1 mM pepstatin, 1 mM leupeptin, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). Protein concentration was determined using the bicinchoninic acid assay (Pierce, Rockford, IL, USA) and equal amounts of protein (20 mg per lane) were separated by SDSÀ-PAGE. Proteins were blotted onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). The membranes were blocked for 1 h in PBST (PBS, 0.05% Tween-20) containing 3% nonfat dry milk and incubated with the primary antibody (1 : 1000) for 2 h. After washing, secondary anti-mouse biotinylated antibody (Vector Laboratories, Burlingame, CA, USA) was used at 1 : 1000 in PBST, applied for 1 h, and detected with horseradish peroxidase-conjugated streptavidin (1 : 2000) (Jackson ImmunoResearch, West Grove, PA, USA). Finally, the membrane was washed in PBST again and the ECL-enhanced chemiluminescence system from Amersham (Braunschweig, Germany) was used to visualize the protein bands in question. For control of equal protein loading, membranes were stripped and reprobed with an antibody against b-actin.
Immunofluorescence analysis
Cells were grown on glass slides, washed with PBS, fixed with 3.5% paraformaldehyde and permeabilized with 0.2% Triton in PBS. After incubation with the monoclonal antibody, an FITC-labeled sheep anti-mouse Ig antibody (Chemicon, Temecula, CA, USA) was used. Nuclei were stained with 0.5 mg/ml DAPI. UV fluorescence photographs were taken on an inverse microscope (IX70, Olympus, Hamburg, Germany) using Kodak ectachrome 400.
